drugset
Drugs / milatuzumab
last change Oct 2015 re-read 2 minutes ago

milatuzumab

also known as hLL1 · IMMU-115 · EPB-1

Monoclonal antibody targets CD74

Developed for
chronic lymphocytic leukemia/small lymphocytic lymphoma · plasma cell myeloma · graft versus host disease · lymphoma · plasmacytoma · systemic lupus erythematosus
Investigated by
Gilead Sciences · Beth Christian · Kaplan Medical Center · Ohio State University · United States Department of Defense · Weill Medical College of Cornell University

Trials 7 · a red edge is where a trial was stopped

today NCT01663766 · Ph 1 NCT00989586 · Ph 1/2 NCT00868478 · Ph 1/2 NCT00603668 · Ph 1/2 NCT00504972 · Ph 1 NCT01845740 · Ph 1 NCT00421525 · Ph 1/2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01663766 Dec 2013 → Mar 2015 chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia, graft versus host disease, myelodysplastic syndrome +1 Gilead Sciences Terminated No outcome recorded
Phase 1 NCT00504972 Jun 2007 → Apr 2011 chronic lymphocytic leukemia/small lymphocytic lymphoma Weill Medical College of Cornell University Completed No outcome recorded
Phase 1 NCT01845740 Jan 2007 → Jun 2009 central nervous system lupus, discoid lupus erythematosus, lupus nephritis Gilead Sciences Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT00989586 Sep 2009 → Apr 2015 lymphoma Beth Christian Completed No outcome recorded
Phase 1/2 NCT00868478 Apr 2009 → Apr 2011 chronic lymphocytic leukemia/small lymphocytic lymphoma Kaplan Medical Center Unknown No outcome recorded
Phase 1/2 NCT00603668 Aug 2008 → Jan 2013 chronic lymphocytic leukemia/small lymphocytic lymphoma Gilead Sciences Completed No outcome recorded
Phase 1/2 NCT00421525 Jan 2007 → Jun 2009 plasma cell myeloma, plasmacytoma Gilead Sciences Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as milatuzumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT00989586 ↗
5

NCT00603668 ↗

NCT00868478 ↗

NCT01663766 ↗

NCT00421525 ↗

NCT01845740 ↗
Known as EPB-1 “Immunomedics has developed hLL1 (previously designated EPB-1), which is a CDR-grafted, fully humanized monoclonal antibody specifically targeting CD74.38” NCT00504972 ↗
Known as hLL1 “A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients...” NCT01663766 ↗
3

“Milatuzumab (hLL1, IMMU-115), a humanized anti-CD74 monoclonal antibody.” NCT00603668 ↗

“milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody” NCT00989586 ↗

NCT00504972 ↗
Known as IMMU-115 “This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen” NCT01663766 ↗
2

“Milatuzumab (hLL1, IMMU-115), a humanized anti-CD74 monoclonal antibody.” NCT00603668 ↗

“milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody” NCT00989586 ↗
Modality Monoclonal antibody “milatuzumab (humanized anti-CD74 monoclonal antibody)” PMID 24112026 ↗ Sep 2013
Route Intravenous “hLL1 administered intravenously” NCT00504972 ↗
Target CD74 “CD74, expressed in multiple myeloma (MM), was evaluated as a target for immunotherapy with milatuzumab” PMID 24112026 ↗ Sep 2013